Regenerative Medicine for Heart Conditions Explained

Many people who get in touch with us want to understand, in plain terms, what we actually mean when we talk about regenerative medicine and the heart. It sounds technical, but the idea at its core is fairly simple: using the body’s own repair materials to help damaged heart muscle recover some of its function. This page sets out what the science involves, how it is being studied, and where it currently stands, without overstating what is known.

What do we mean by “regenerative medicine” in heart disease?

Conditions such as a heart attack, heart failure or cardiomyopathy damage heart muscle. Once muscle tissue is injured in this way, the heart often cannot replace it on its own, which is why symptoms such as breathlessness and fatigue can persist or worsen over time. Regenerative medicine is the area of research looking at whether the heart’s own repair processes can be supported or encouraged, rather than only managing symptoms with medication. Adult stem cells, taken from a patient’s own body, are one of the main tools being studied for this purpose. The Heart Cells Foundation has funded research into this approach for many years, and continues to do so.

How is this thought to work?

Adult stem cells are sometimes described as the body’s building blocks, because they have the capacity to support repair in damaged tissue. Researchers have studied whether introducing a patient’s own stem cells into an area of injured heart muscle might help that tissue recover some of its function. This is different from surgery or medication, which are typically aimed at managing symptoms, improving blood flow mechanically, or easing the heart’s workload. The research our charity has supported focuses specifically on using a patient’s own cells, harvested from their own bone marrow, rather than cells from another source.

Where the evidence has come from

Our charity funded Phase I and Phase II of the REGENERATE trials, which looked at this approach in different groups of patients. We are not asking you to take our word for the detail: results from this research have been published in medical literature, and we summarise them honestly on our clinical trials page.

Treating patients soon after a heart attack

One strand of research, REGENERATE-AMI, looked at whether it was possible to treat patients with cell therapy within twenty-four hours of a heart attack. The trial found this approach was safe and that it helped the heart recover, with results published in medical literature.

Dilated cardiomyopathy

A separate trial, REGENERATE-DCM, treated patients with dilated cardiomyopathy, a form of heart failure. Patients treated with cell therapy showed improvements in cardiac function, exercise capacity, quality of life, heart failure symptoms and certain biochemical markers associated with heart failure. These results have also been published in medical literature.

Ischaemic heart failure

REGENERATE-IHD treated patients with ischaemic heart failure, caused by narrowed coronary arteries. Patients in this trial showed improvements in cardiac function, heart failure symptoms, quality of life scores and biochemical markers of heart failure. As with the other trials, these findings have been published in medical literature.

Why this matters for patients and families

We understand that when a family member has been told there are no further treatment options, any mention of stem cells can raise hopes quickly. We try to be careful here. The research so far shows improvements for many patients studied; it does not show that this approach works for everyone, is a cure, or removes the underlying heart condition. It is one area of active, serious scientific enquiry, built on real trial data rather than promises. If you would like to read what trial and treated patients have said in their own words, our patient case studies set out individual experiences, which will naturally vary from person to person.

What stage is this research at now?

Phase I and II of the REGENERATE trials have been completed and funded by our charity, with their results published. A larger study, BAMI, took place across Europe and has been described as one of the most significant contemporary studies in this field, with implications for future research involving both heart attack patients and cell therapy more broadly. Planning and fundraising for Phase III is under way; this phase is intended to generate the scale of evidence needed before any treatment could be considered for wider adoption. Phase III is not yet recruiting patients. You can read more about the trials programme on our clinical trials page.

The Compassionate Treatment Programme

Alongside the trials, our charity funds a Compassionate Treatment Programme at St Bartholomew’s Hospital, London, the first unit of its kind in Europe. This programme treats patients with heart failure caused by idiopathic dilated cardiomyopathy or ischaemic heart disease, using their own stem cells, on compassionate grounds where previous trial results have shown improvement in these conditions. It is not a general treatment service and has specific suitability criteria. If you or a family member are wondering whether this might be relevant, the right first step is always to speak with your own cardiologist or GP. You can also read about who the programme is designed for on our Compassionate Unit page, and find answers to common questions on our compassionate programme questions page.

Supporting continued research

None of this research happens without funding. Our charity pays for the ongoing work of the Compassionate Treatment Programme and for the planning of Phase III, and we rely entirely on the generosity of supporters to do so. If this page has helped you understand the science more clearly, you may also like to learn about the people and history behind our work on our about page, or consider supporting future research through a donation.

Contact

If you have questions about the research described here, or about whether the Compassionate Treatment Programme might be relevant to your circumstances, please do get in touch. You can call us on 020 7935 5351, message us via our Facebook page, or reach out through our contact page. Please remember we cannot give individual medical advice; your own cardiologist or GP is best placed to discuss your specific situation.

Currently Browsing: Regenerative Medicine for Heart Conditions Explained